February 20, 2018
WELLESLEY, Mass., Feb. 20, 2018 -- The predicted increases in the use of biologics worldwide, as well as the increasing number of new biologics entering the market, are driving growth in the biological safety testing market. In a new report, Biologics Development and Manufacturing Testing: Technologies and Global Markets, BCC Research estimates the global biological safety testing market to reach $5.1 billion and $13.1 billion in 2017 and 2022, respectively, at a CAGR of 20.9%.
This comprehensive report focuses on the key market segments: in vivo (or lab animal-based testing), in vitro (which includes both test tube and automated testing as well as cell and tissue-based testing), and analytical testing (which includes services and products offered by analytical testing labs). Biological safety testing is an integral part of the protein-based drug and vaccine discovery, development and commercialization process. Utilizing data obtained in vivo about physical, chemical and biological processes, and in conjunction with in vitro data obtained from chemical and cell–based testing assays, the safety and efficacy of new biologics and those in development stages are assessed.
A strong pharmaceutical product pipeline will aid the growth of the pharmaceutical and biotechnology industries, which are the major end users of biological safety testing products and services. Moreover, increasing government support for the pharmaceutical and biotechnology industries will further boost the demand for Biological Safety Testing.
Increasingly, the trend among large biopharmaceutical companies is to outsource the majority of their Biological Safety Testing needs to smaller, independent contract laboratories for final analysis and verification. This is because smaller laboratories have the resources to run high throughput testing arrays faster and more efficiently than larger biopharmaceutical companies can perform using in-house testing.
“The global demand for new and approved biologics is increasing due to higher incidences of acute and chronic disease in populations across the globe,” said David Peters, BCC Research analyst and author of the report. “The promise of biologics is targeted efficacy and relative safety as compared to many other small molecule-based drugs. Biological safety testing is an integral part of the new biologics’ discovery, development and commercialization life cycle. Increasing requirements by regulatory agencies, such as the FDA and ICH, are driving need for such testing as well as creating greater stringencies in testing accuracy and standardization.”
Editors/reporters requesting analyst interviews should contact firstname.lastname@example.org.
Biologics Development and Manufacturing Testing: Technologies and Global Markets( BIO155A )
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email email@example.com or visit www.bccresearch.com/media to request access to our library of market research.